


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A composition ~~Composition~~ containing an androgenic  $11\beta$ -halogen steroid, ~~selected from the group of compounds of general of~~ formula I



in which

X-Y-Z represents a group with one of the two structures  $\text{CH}=\text{C}-\text{C}$  or  $\text{CH}_2-\text{C}=\text{C}$ ,


$\text{R}^1$  can be in  $\alpha$ -position and  $\beta$ -position and stands for hydrogen, R or P-Q-R that is bonded via P to the basic ring structure, provided that no substituent  $\text{R}^1$  is present on Z if X-Y-Z represents the group  $\text{CH}_2-\text{C}=\text{C}$ , whereby

P and Q each independently represents a represent straight-chain or branched-chain  $\text{C}_1$ - to  $\text{C}_8$ -alkylene, -alkenylene, or -alkynylene group groups or a fluorinated straight-chain or branched-chain  $\text{C}_1$ - to  $\text{C}_8$ -alkylene, -alkenylene, or -alkynylene group their fluorinated derivatives and can be the same or different, and whereby

R represents a  $\text{CH}_3$  or  $\text{CF}_3$  radical, provided that no substituent  $\text{R}^1$  is present on Z if X-Y-Z represents the group  $\text{CH}_2-\text{C}=\text{C}$ ,

$R^6$  is a hydrogen atom or stands for R or P-Q-R that is bonded via P to the ring structure ~~can have the meanings that are indicated under  $R^7$ ,~~  
 $R^7$  stands for R or P-Q-R that is bonded via P to the ~~basic~~ ring structure,  
~~whereby these groups have the previously mentioned meanings,~~  
 $R^{11}$  represents a halogen,  
 $R^{13}$  is methyl or ethyl, and  
 $R^{17}$  is hydrogen or stands for  $C(O)-R^{18}$ , whereby  
 $R^{18}$  is a straight-chain or branched-chain  $C_1$ - to  $C_{18}$ -alkyl, -alkenyl, or -alkinyl radical or an aryl radical, or stands for T-U-V that is bonded via T P to the  $C(O)$  group, which  $R^{18}$  group is optionally substituted with one or more  $NR^{19}R^{20}$  or  $SO_xR^{21}$ .  
x is 0, 1 or 2,  
 $R^{19}, R^{20}$   
and  $R^{21}$  in each case are hydrogen or T-U-V that is bonded via T to N or S, whereby  
T and U each independently represents a ~~represent~~ straight-chain or branched-chain  $C_1$ - to  $C_{18}$ -alkylene, -alkenylene, -alkinylene group ~~groups~~, alicyclic  $C_3$ - to  $C_{12}$  group ~~groups~~ or aryl group, ~~groups and are the same or different, and~~  
V is a straight-chain or branched-chain  $C_1$ - to  $C_{18}$ -alkyl-, -alkenyl- or -alkinyl radical or an aryl radical, or  
 ~~$R^{18}$  has one of the previously mentioned meanings and in addition is substituted with one or more groups  $NR^{19}R^{20}$  or one or more groups  $SO_xR^{21}$ , whereby x = 0, 1 or 2, and  $R^{19}, R^{20}$  and  $R^{21}$  in each case are hydrogen or T-U-V that is bonded via T to N, S with the previously mentioned meaning,~~  
or a pharmaceutically acceptable salt thereof ~~provided that in addition, the physiologically compatible addition salts with inorganic and organic acids are included,~~

and the gestagen of the formula below:




2. (Currently Amended) The composition ~~Composition~~ according to claim 1, wherein the compound of ~~characterized in that the~~ 11β-halogen steroid of general formula I is ~~the compound~~ 11β-fluoro-17β-hydroxy-7α-methyl-estr-4-en-3-one.

3. (Currently Amended) A pharmaceutical ~~Pharmaceutical~~ composition containing a composition according to claim 1 and ~~as well as~~ a pharmaceutically compatible vehicle and/or adjuvant ~~adjuvants~~.

4. (Currently Amended) The pharmaceutical ~~Pharmaceutical~~ composition according to claim 3, wherein the compound of ~~11β-halogen steroid of general~~ formula I is ~~the compound~~ 11β-fluoro-17β-hydroxy-7α-methyl-estr-4-en-3-one.

5. (Currently Amended) A male ~~Male~~ contraceptive agent, which is a combination of an androgenic 11β-halogen steroid of formula I



in which

X-Y-Z represents  $\text{CH}=\text{C}-\text{C}$  or  $\text{CH}_2-\text{C}=\text{C}$ ,

$\text{R}^1$  can be in  $\alpha$ -position and  $\beta$ -position and stands for hydrogen, R or P-Q-R that is bonded via P to the ring structure, provided that no substituent  $\text{R}^1$  is present on Z if X-Y-Z represents  $\text{CH}_2-\text{C}=\text{C}$ ,

P and Q each independently represents a straight-chain or branched-chain  $\text{C}_1$ - to  $\text{C}_8$ -alkylene, -alkenylene, or -alkynylene group or a fluorinated straight-chain or branched-chain  $\text{C}_1$ - to  $\text{C}_8$ -alkylene, -alkenylene, or -alkynylene group

R represents a  $\text{CH}_3$  or  $\text{CF}_3$  radical,

$\text{R}^6$  is a hydrogen atom or stands for R or P-Q-R that is bonded via P to the ring structure,

$\text{R}^7$  stands for R or P-Q-R that is bonded via P to the ring structure,

$\text{R}^{11}$  represents a halogen,

$\text{R}^{13}$  is methyl or ethyl,

$\text{R}^{17'}$  is hydrogen or stands for  $\text{C}(\text{O})-\text{R}^{18}$ ,

$\text{R}^{18}$  is a straight-chain or branched-chain  $\text{C}_1$ - to  $\text{C}_{18}$ -alkyl, -alkenyl, or -alkynyl radical or an aryl radical, or stands for T-U-V that is bonded via T to the  $\text{C}(\text{O})$  group, which  $\text{R}^{18}$  group is optionally substituted with one or more  $\text{NR}^{19}\text{R}^{20}$  or  $\text{SO}_x\text{R}^{21}$ ,

x is 0, 1 or 2,

R<sup>19</sup>, R<sup>20</sup>


and R<sup>21</sup> in each case are hydrogen or T-U-V that is bonded via T to N or S,

T and U each independently represents a straight-chain or branched-chain C<sub>1</sub>- to C<sub>18</sub>-alkylene, -alkenylene, -alkynylene group, alicyclic C<sub>3</sub>- to C<sub>12</sub> group or aryl group,

V is a straight-chain or branched-chain C<sub>1</sub>- to C<sub>18</sub>-alkyl-, -alkenyl- or -alkynyl radical or an aryl radical,

or a pharmaceutically acceptable salt thereof,

and the gestagen of the formula below



containing a pharmaceutical composition according to claim 3.

6. (Currently Amended) The male Male contraceptive agent according to claim 5, wherein the compound of formula I is 11 $\beta$ -fluoro-17 $\beta$ -hydroxy-7 $\alpha$ -methyl-estr-4-en-3-one containing a pharmaceutical composition according to claim 4.

7. (Currently Amended) The male Male contraceptive agent according to claim 5, wherein the androgenic compound of general formula I is formulated

pharmaceutically such that it is suitable to the latter can be implanted in the body of ~~the a~~ male user ~~over an extended period~~ such that the androgenic compound is released continuously as an extended release formulation to ~~over this extended period to the organism~~ of the user.

8. (Currently Amended) The male Male contraceptive agent according to claim 5, wherein the androgenic compound of ~~general~~ formula I is provided therein for oral administration.

9. (Currently Amended) The male Male contraceptive agent according to claim 5, wherein the gestagen therein is formulated pharmaceutically such that it is released to the body of the male user as an extended release formulation ~~over an extended period~~.

10. (Currently Amended) The male Male contraceptive agent according to claim 9, wherein the gestagen is formulated such that it is suitable to the latter can be implanted in the body of ~~a the~~ male user over an extended period, such that the gestagen is released continuously as an extended release formulation to ~~over this extended period to the organism of the user~~.


11. (Currently Amended) The male Male contraceptive agent according to claim 10, wherein the gestagen is formulated such that it is suitable for administration transdermally in a transdermal system.

12. (Currently Amended) The male Male contraceptive agent according to claim 5, wherein the gestagen is formulated for oral administration.

13. (New) A method of male contraception, comprising administering to a male a composition according to claim 1.

14. (New) A method of male contraception, comprising administering to a male a composition according to claim 2.

15. (New) A method of male contraception, comprising administering to a male an androgenic  $11\beta$ -halogen steroid of formula I



in which

X-Y-Z represents  $\text{CH}=\text{C}-\text{C}$  or  $\text{CH}_2-\text{C}=\text{C}$ ,

$\text{R}^1$  can be in  $\alpha$ -position and  $\beta$ -position and stands for hydrogen, R or P-Q-R that is bonded via P to the ring structure, provided that no substituent  $\text{R}^1$  is present on Z if X-Y-Z represents  $\text{CH}_2-\text{C}=\text{C}$ ,

P and Q each independently represents a straight-chain or branched-chain  $\text{C}_1$ - to  $\text{C}_8$ -alkylene, -alkenylene, or -alkynylene group or a fluorinated straight-chain or branched-chain  $\text{C}_1$ - to  $\text{C}_8$ -alkylene, -alkenylene, or -alkynylene group

R represents a  $\text{CH}_3$  or  $\text{CF}_3$  radical,

$\text{R}^6$  is a hydrogen atom or stands for R or P-Q-R that is bonded via P to the ring

structure,

$R^7$  stands for R or P-Q-R that is bonded via P to the ring structure,

$R^{11}$  represents a halogen,

$R^{13}$  is methyl or ethyl,

$R^{17'}$  is hydrogen or stands for  $C(O)-R^{18}$ ,

$R^{18}$  is a straight-chain or branched-chain  $C_1$ - to  $C_{18}$ -alkyl, -alkenyl, or -alkinyl radical or an aryl radical, or stands for T-U-V that is bonded via T to the  $C(O)$  group, which  $R^{18}$  group is optionally substituted with one or more  $NR^{19}R^{20}$  or  $SO_xR^{21}$ ,

x is 0, 1 or 2,

$R^{19}$ ,  $R^{20}$


and  $R^{21}$  in each case are hydrogen or T-U-V that is bonded via T to N or S,

T and U each independently represents a straight-chain or branched-chain  $C_1$ - to  $C_{18}$ -alkylene, -alkenylene, -alkinylene group, alicyclic  $C_3$ - to  $C_{12}$  group or aryl group,

V is a straight-chain or branched-chain  $C_1$ - to  $C_{18}$ -alkyl-, -alkenyl- or -alkinyl radical or an aryl radical,

or a pharmaceutically acceptable salt thereof,

and the gestagen of the formula below





16. (New) A method according to claim 15, wherein the androgenic  $11\beta$ -halogen steroid of formula I is  $11\beta$ -fluoro- $17\beta$ -hydroxy- $7\alpha$ -methyl-estr-4-en-3-one.